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As an investigational fibrinolytic agent for acute myo-
cardial infarction, intravenous recombinant tissue-type
plasminogen activator (rt-PA) has been administered
primarily in tertiary care and university centers. To
determine the value of early initiation of such therapy,
two satellite community hospital emergency rooms were
established for use of rt·PA and the experience was com-
pared among 142 consecutive patients who were trans-
ferred to a regional center for acute cardiac catheter-
ization after intravenous rt-PA therapy. In Group I (n
= 19), patients received rt-PA after interhospital trans-
port to the regional center, but before cardiac catheter-
ization. In Group II (n = 70), rt-PA therapy was ini-
tiated by the helicopter physician and nurse team after
their arrival at the local community hospital emergency
room. Group III patients (n = 53) had rt-PA admin-
istered in the local community hospital by the emergency
room physician.
Recombinant tissue-type plasminogen activator (rt-PA) was
first introduced as an intravenous fibrinolytic agent in 1984
(I). Over the past 3 years, >3,000 patients with acute myo-
cardial infarction have been treated with rt-PA (2). Because
this agent has been under clinical investigation, patients
have been treated relatively late after symptom onset-4.8
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Group III patients had earlier initiation of therapy
(2.1 ± 0.8 hours in Group III versus 3.8 ± 1.2 hours
in combined Groups I and II, p < 0.001) and an in-
creased rate of infarct vessel recanalization on the 90
minute coronary angiogram (81in Group III versus 67%
in combined Groups I and II, p = 0.057). The patients
in Group III had a higher acute left ventricular ejection
fraction (54 ± 8% versus50 ± 9.5% in combinedGroups
I and II, p < 0.01) and a trend toward an increased 7
day ejection fraction (55.5 ± 9% versus 51.7 ± 9.5%,
respectively, p = 0.08).
In conclusion, community hospital administration of
intravenous rt-PA in patients with acute myocardial in-
farction is safe, significantly minimizes the time delay of
initiating therapy and is associated with improved fi-
brinolytic efficacy and global ventricular function.
(J Am Coll CardioI1987;1O:1l73-7)
hours in the Thrombolysis in Myocardial Infarction (TIMI)
Phase I trial (3) and 3.9 hours in the Thrombolysis and
Angioplasty in Myocardial Infarction (TAM}) pilot trial (4).
This time delay occurred as a result of the original require-
ment for a pretreatment coronary angiogram (1,3) or the
need for interhospital transport before initiation of ther-
apy (5).
As our experience with intravenous rt-PA therapy ac-
crued, attempts to decrease the delay in the initiation of
therapy were made. After in-service education and regu-
latory board approval, rt-PA was ultimately made available
for use in two satellite community hospital emergency rooms.
In this study, we report the clinical and angiographic results
in 142 consecutive patients with acute myocardial infarction
transferred to our center for cardiac catheterization after
intravenous rt-PA therapy.
0735-1097/87/$3.50
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Methods
Study patients. The following selection criteria were
used: I) chest pain unrelieved by nitroglycerin, lasting >20
minutes to <6 hours; 2) 0.1 mV electrocardiographic (ECG)
ST segment elevation in two or more contiguous leads; 3)
age :575 years; 4) absence of a predisposition to bleeding;
5) no prior coronary artery bypass surgery or myocardial
infarction in the same arterial distribution; and 6) no recent
stroke, surgery or trauma. All patients in the study were
transferred from two outlying community hospital emer-
gency rooms located 37 and 54 miles, respectively, from
the University of Michigan Medical Center. Neither the
Foote Hospital in Jackson nor South Macomb Hospital in
Warren has cardiac catheterization laboratory facilities.
Three groups of patients were classified on the basis of
the mode of intravenous rt-PA initiation. In Group I, 19
patients received rt-PA after transport from the community
hospital to our facility. Group JI patients (n = 70) received
rt-PA in the community hospital after arrival of the heli-
copter flight physician and nurse. Groups I and II represent
the early experience, before regulatory board approval was
given to have rt-PA supplied directly in the community
hospital emergency rooms. In Group III, 53 patients re-
ceived intravenous rt-PA in the community hospital emer-
gency room as soon as the diagnosis of acute myocardial
infarction was made. Transport was by helicopter for 43
patients and by ground ambulance for 10 patients in this
group; the transport time was 17 ± 9 and 40 ± 12 minutes,
respectively.
Cardiac catheterization. After informed consent was
obtained, intravenous rt-PA was administered in a dose of
either 60 mg or 1.0 mg/kg body weight (90 mg maximum)
over the first hour, with the remainder of 100 to 150 mg
infused over the next 5 to 6 hours. All patients received
10% of the first hour dose as a bolus injection. At the 90
minute point of rt-PA infusion, coronary arteriography of
the infarct-related vessel was performed. On the basis of
the fourth injection (or final injection if fewer than four
views were obtained), arterial patency was determined using
the TIMI grade classification (3). Left ventriculography was
also performed. Immediate coronary angioplasty was uti-
lized for all patients whose infarct-related vessel failed to
recanalize 90 minutes after initiation of rt-PA therapy and
for those patients randomized to undergo this procedure (4).
All patients were treated with intravenous heparin (500 to
1,000 U/h) for a minimum of 3 days, diltiazem 30 to 60
mg four times/day and aspirin 325 mg/day. Beta-receptor
blocker medication was not initiated during the hospitaliza-
tion unless it was needed to treat supraventricular tachy-
cardia, hypertension or postinfarction angina.
Repeat cardiac catheterization was performed at 7 to 10
days. Patients with recurrent ischemia, defined as ~20 min-
utes of chest discomfort associated with ECG ST segment
changes in the infarct territory, had emergency catheteriza-
tion. Coronary angioplasty or bypass surgery was performed
as clinically indicated for the patients who developed re-
current ischemia.
All cineangiographic films were analyzed with the in-
vestigator unaware of patient identity, time of acquisition
and type of therapy. The left ventricular ejection fraction
was determined by the area-length method (6). Infarct vessel
patency was defined as TIMI grade 2 or 3; failure to re-
perfuse included TIMI grades 0 or I (3). Ventriculograms
that were technically poor because of either inadequate con-
trast filling or frequent ventricular ectopic activity were ex-
cluded from the analysis.
Statistical analysis. Values expressed are mean ± I
standard deviation unless otherwise stipulated. Fisher's ex-
act test was used to determine the rate of infarct vessel
recanalization for Group III versus that for Group I and II
patients. Time from onset of chest pain to rt-PA therapy
and determination of ejection fraction (immediate and con-
valescent) were compared among groups using a Wilcoxon
rank sum test.
Results
Patient characteristics. Of 142 consecutive patients
transferred for acute intervention, 19 patients (Group I) did
not receive rt-PA until after arrival at our facility. In these
patients, thrombolytic therapy was started before cardiac
catheterization. In Group II (n = 70), the University-based
helicopter crew flew rt-PA to the community hospital emer-
gency room. Then the flight physician and nurse started the
rt-PA infusion before the return trip. Group III patients (n
= 53) had rt-PA administered by the community hospital
emergency room physician and nurse team as soon as pro-
tocol entry criteria were met. Group I and II patients did
not receive rt-PA in the community hospital because direct
availability of the investigational drug had not been ap-
proved by the regulatory board. Because of the relatively
small number of Group I patients and the inherent time delay
associated with initiation of therapy in the first two groups,
data for Groups I and II are pooled for the purpose of the
subsequent analysis. In Table I, baseline demographic and
angiographic characteristics for the three groups are pre-
sented. Despite differences in the first hour dosing regimens
of rt-PA during the study period, the dose of rt-PA was
similar in the three groups.
Tip-ling of fibrinolytic therapy and infarct vessel pa-
tency. The time from onset of chest discomfort to initiation
of intravenous rt-PA was shorter in Group III compared
with Group I and II patients (2.1 ± 0.8 for Group III versus
3.8 ± 1.2 hours for Groups I and II, p < 0.001) (Fig. I).
The results of infarct vessel patency, as determined by the
final 90 minute coronary angiogram (Table 2), suggested a
trend toward increased recanalization in Group III versus
Group I and II patients (81 versus 67%, p = 0.057).
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Table I. Baseline Characteristics of 142 Patients* Table 2. In farct Vessel Patency and Ventricular Function in
142 Patients
*Group III is compared with Groups I and II .
II was observed (55.5 ± 9% in Group III versus 5 J.5 ±
9.5%inGroups I and II, p = 0.08). There werenosignificant
differences between groups with respect to baseline vari-
ables among patients without technically adequate ventric-
ulograrns.
Interrupted myocardial infarction and misdiagnosis.
Although all patients in the study fulfilled entry criteria.
eight patients (5.6%) did not develop enzymatic evidence
of myocardial infarction. In Group I. one patient with nor-
mal coronary arteries at acute angiography subsequently
developed a friction rub and pleuritic chest pain and was
diagnosed as having pericarditis. Another patient in this
group was found to have only minimal irregularities of the
right coronary artery associated with a posterobasal wall
motion abnormality. Although he did not fulfill enzymatic
criteria for myocardial infarction, the patient developed re-
current chest pain and ECG ST segment elevation. At emer-
gency repeat angiography. a high grade right coronary artery
stenosis was present. responsive to intracoronary nitroglyc-
erin, and on this basis coronary artery spasm was diagnosed.
Three patients in Group II and two patients in Group III
did not demonstrate significant (>5%) creatine kinase MB
fraction elevation, despite an elevated total creatine kinase
(245 ± 20) and fulfillment of electrocardiographic criteria
at the time of study entry. In all five patients. tight residual
stenosis of the infarct vessel was present associated with a
regional wall motion abnormality. Clinically, it was be-
lieved these patients had experienced an ., interrupted" myo-
cardial ischemic event. such that early recanalization led to
undetectable myonecrosis. Despite a duration of 1.9 ± 0.6
hours of symptoms, these patients may not have had total
occlusion of the infarct vessel. An additional patient in
Group II was found to have normal coronary arteries, with
reversion of ST segment elevation to normal during exer-
Group I Group II Group III p
In =19) (n=70) (n= 53) Value"
Group I Group II Group III
(n = 19) (n = 70) (n =53)
Age (yr) 56 :±: II 55 :±: 9 56 :±: 10
Sex (% male) 79 76 74
Infarct vessel
LAD (%) 37 36 3M
LCx (%) II 13 15
RCA (%) 51 51 47
Multivessel disease (%) 42 39 36
Dose of rt-PA (first hour [mg]) 69 :±: 8 73 ::: 9 74 ::: 10
Time of final angiogram (min) 88 :±: 6 95 ::: 7 94 =II
*There were no significanl (p < 0.05) differences among groups.
LAD = left anterior descending; LCx = left circumflex: RCA =' right
coronary artery; rt-PA =' recombinant tissue-type plasminogen activator.
Clinical course. During transport of the 142 patients.
no deaths. significant bleeding or episodes of ventricular
fibrillation occurred. Nonsustained ventricular tachycardia.
not requiring cardioversion, and accelerated idioventricular
rhythm occurred in 5 and 4% of the patients. respectively.
with no significant intergroup differences. Sustained hy-
potension and severe sinus bradycardia or atrioventricular
block were manifest in 2 and 12% of the study patients.
respectively, without differences among groups.
The in-hospital mortality rate, frequency of coronary an-
gioplasty or coronary bypass graft procedures during the
hospital course and incidence of recurrent ischemia are listed
in Table 3. Although there was a lower mortality in Group
III patients, the difference was not statistically significant.
In the subsequent 8 ± 3 month follow-up of the 135patients
who survived the hospitalization, there has been only one
death. which occurred in a patient in Group II.
Left ventricular function (Table 2). Group III patients
had a higher immediate ejection fraction than did patients
in Groups I and II (54 ± 8% in Group III versus 50 ±
9.5% in Groups I and II. p < 0.01). Follow-up ventricu-
lography performed at 7 to 10 days was accomplished in
96% of surviving patients. A trend for higher 7 day ejection
fraction in Group III patients compared with Groups I and
Figure I. Timing of intravenous recombinant tissue plasminogen
activator administration . A significant reduction from onset of
chest pain (CP) to intravenous therapy was observed for the rural
hospital-initiated strategy group (Group III) compared with the
other two groups (Groups I and II). Cath Lab = catheterization
laboratories.
Infarct vessel patency (90 min)
Acute ejection fraction (%)
No. technically adequate
7 day ejection fraction (%)
No. technically adequate
68% 66'*
49 ::: 9 50::: 10
( 16) (62)
51 =10 52 j: 9
( 14) (56)
MI'X
54 j: 9
(47)
55.5 :±: 9
(42 )
0.057
< 0.0 1
0.08
CABG = coronary artery bypass surgery; PTCA
transluminal coronary angioplasty.
Table 3. Clinical Course of 142 Patients3 9±1.0
< 4 37±1.3~
; 3
Q.
U 2.1±0 8
~ 2 N~ 1 9 N.70
p<O .OOl
:!:. N=53
ClI
E
i= 0
Cath Helicopter Rural
Lab
Mortality ( % )
PTCA ( 'If)
CABG ( 'Ye)
Recurrent ischemia (%)
Group I
5.2
63
16
26
Group II
5.7
60
17
21
Group III
3.7
60
15
25
percutaneous
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cise. Early repolarization and atypical chest pain were the
clinical diagnoses in this patient.
Discussion
Our results demonstrate that early administration of in-
travenous recombinant tissue-type plasminogen activator (rt-
PA) in the community hospital is safe. It is associated with
a high infarct vessel recanalization rate and preservation of
ventricular function as compared with strategies with an
intrinsic delay in administering fibrinolytic therapy.
Previous work with streptokinase. Previous studies
have emphasized the importanceof early streptokinase ther-
apy for improvingclinical outcomeand ventricular function.
In the largest published clinical trial of myocardial reper-
fusion, the Gruppo Italianoper 10 StudiodellaStreptochinasi
Nell'lnfarto Miocardico (GISSI) investigators (7) random-
ized 1,277 patients treated within I hour from onset of
symptoms and demonstrated nearly 50% reduction in acute
mortality for patients receivingstreptokinase comparedwith
conventional therapy. At I year follow-up (8), a significant
and persistent advantage in survival in the streptokinase
versusthe conventional therapygroup was maintained. Sim-
ilar resultsof mortality reductionin theGISSI trial, although
less striking. were observed in patients treated more than 3
hours from symptom onset. The International Studies of
InfarctSurvival (lSIS-2) trial (9) recently reportedmortality
results in 4,000 patients randomized to either intravenous
streptokinase or placebo within 4 hours of symptom onset.
Patients receivingthrombolytic therapyhad a 33% reduction
in mortality (12% placebo group, 8% mortality treatment
group). These results further confirm the mortality-sparing
effects of early thrombolytic treatment.
Other studies (10-12) have documented the advantage
of very early streptokinase administration in preserving left
ventricular function. Using home administration of intra-
venous streptokinase, Fine et al. (II) treated the majority
of their patients by <2 hours from symptom onset and
demonstrated nearly intact ventricularejection fraction, de-
termined by ventriculography performed at 6 days. Simi-
larly, infarct size was reduced in patients treated by 2 hours
compared with 2 to 4 hours from symptom onset (10, II).
An inverse relation of time to thrombolytic therapy versus
predischarge ventriculographic ejection fraction was ob-
served by Mathey et al. (12). Taylor et al. (13) published
their experienceof intravenous streptokinaseadministration
in the community hospital before patient transfer for early
coronary angiography. Using this strategy, a high rate of
thrombolytic efficacy was observedand ventricularfunction
was improved compared with that in a similar cohort of
patients treated with intracoronary streptokinase (13).
Time dependency of fibrinolytic therapy. The Throm-
bolysis in Myocardial Infarction (TIMI) trial (14) demon-
strated an important time-dependent relation for streptoki-
nase-mediated infarct artery recanalization . After 3 hours
from onset of symptoms, the thrombolytic efficacy for in-
travenous streptokinase approached the level associatedwith
spontaneous recanalization. This was not apparent to the
same degree for intravenous (rt-PA).
The results of the present study are the first to suggest
increased arterial patency with earlier intravenous rt-PA
administration. With similar rt-PA dosing and timing of
angiography, a >80% recanalization rate was achieved in
the group of patients treated at approximately 2 hours from
the onset of symptoms. At 3.5 to 4 hours, the efficacy was
significantly reduced to 65%, although the patency level
was substantially higher than that associated with strepto-
kinase (3) or spontaneous reperfusion (approximately20%).
Although time-dependent thrombolytic efficacy with rt-PA
may not be as critical as with streptokinase, our results
suggestthatoptimal reperfusion rates maybe achievedwhen
rt-PA is initiatedveryearly. Larger numbersof patients who
receive early thrombolytic therapy and subsequently undergo
acute angiography must be studied to determine whether rt-
PA indeed exhibits time dependency and to compare the
efficacyof rt-PA and other thrombolytic agents in achieving
recanalization efficacy.
Left ventricular function. The current study demon-
strated a higher immediate ejection fraction for patients re-
ceiving intravenous rt-PA therapy in the communityhospital
comparedwithpatientsreceiving delayed therapy. This find-
ing may reflect either actual increased salvage of myocar-
dium by early reperfusion or assessment of ventricular func-
tion before "stunning " has occurred (15). There has been
little previous investigation of the effect of very early re-
perfusion on immediateejection fraction because the major
focus has been on convalescentcardiac function. At I week
follow-up, the trend of a persistently higherejection fraction
for the early treatment group suggests that preservation of
myocardial function was achieved rather than a spuriously
high initial high ejection related to "premature" measure-
ment. Furthermore, our data suggest that myocardial stun-
ning may not be an importanteffect in patients who achieve
rapidreperfusion. The resultsof improvedpredischargeven-
tricular function for patients treated early with rt-PA are
Figure 2. Distribution of cardiac catheterization laboratories (Cath
Lab) and coronary angioplasty (PTCA) centers in hospitals in the
United States. Data are from American Hospital Association 1986
Survey (16) and USC!. Billerica, Massachusetts.
(12.7%) 725 Hospitals-Cardiac
Cath Lab. PTCA
(6.1%) 352 Hospitals-
Cardiac Cath Lab.
No PTCA
(81.2%)
4639 Hospitals-
General Medical Care.
No Cardiac Cath Lab
lACC Vol. 10, No.6
December 1987:1173-7
TOPOL ET AL.
EARLY TISSUE PLASMINOGEN ACTIVATOR ADMINISTRATION
lin
concordant with the previouslycited reports on streptokinase
therapy (10-13),
Need for a regionalized approach. All of the patients
in the current study were transferred from a community
hospital emergency room to our center for emergency coro-
nary angiography, Although the safety of interhospitaltrans-
port of patients with evolving myocardial infarction was in
question, particularly with concurrent thrombolytic therapy,
recent published experience (5) and the present study sup-
port its feasibility and lack of hazard. Only 19% of acute
care general hospitals in the United States in 1986 were
reported to have a cardiac catheterization laboratory (Fig.
2) (16), Coronary angioplasty was available in only two-
thirds of these hospitals, This includes a large proportion
of centers with a low volume and experience (17), partic-
ularly with emergency coronary angioplasty. Thus, to per-
form diagnostic angiography and definitive recanalization
as needed, a regionalized approach is essential.
It is impractical for emergency coronary angiography to
be performed in all patients after early intravenous fibri-
nolytic therapy, However, diagnosis of reperfusion is ac-
curately conferred only by angiography because clinical
bedside markers lack high predictive value (18), Patients
who have unsuccessful thrombolytic therapy may derive
benefit from "salvage" coronary angioplasty, which has
been shown to augment ventricular function (19). This ag-
gressive approach may be especially warranted when ex-
tensive myocardium is at risk or for early presentation of
cardiogenic shock (20), Another subset of patients who may
require urgent interhospital transport are those who develop
recurrent ischemiasoon after intravenous thrombolysis (21),
To preserve myocardial viability, urgent catheterization and
mechanical or surgical revascularization may be necessary.
The present study demonstrates that a regionalized approach
to acute coronary intervention is feasible. The optimal tim-
ing and particular subsets of patients who need urgent car-
diac catheterization will be established by ongoing large-
scale trials. The expense of rapid interhospital transport is
noteworthy because helicopter transport cost is nearly four
times that of ground ambulance (approximately $2,000 ver-
sus $500 per transport [51). With early community hospital
administration of rt-PA, there may be a decreased require-
ment for either rapid transport or absolute need for inter-
hospital transfer.
Conclusions. Initiation of intravenous rt-PA in the com-
munity hospital setting is safe and advantageous. Improved
coronary artery patency and ventricular function suggest that
this form of intravenous fibrinolytic therapy should bebrought
geographically and temporally as close to the patient as
possible.
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